HIV molecular immunology database
CVPTDPNPQEIYMEN
|
gp160(74-88) | B*35:01 human epitope |
CVPTDPNPQEvvlEN
|
gp160(74-88) | subtype-specific susceptible form |
CVPTDPNPQEVVLENVTE
|
gp160(74-91) | human epitope |
PNPQEIYMENVTEEF
|
gp160(79-93) | human epitope |
PNPQEvvlENVTEnF
|
gp160(79-93) | subtype-specific susceptible form |
KQLEK+NVTENFNMWKN
|
gp160(83-98) | human epitope |
IYMENVTEEFNMWKN
|
gp160(84-98) | human epitope |
vvlENVTEnFNMWKN
|
gp160(84-98) | subtype-specific susceptible form |
KNVTENFNMWKNDMVD
|
gp160(87-102) | human epitope |
NVTENFNMW
|
gp160(88-96) | A*25 human epitope |
NVTENFdMW
|
gp160(88-96) | escape documented in this paper; observed variant; replicative capacity reduced |
NVTEhFNMW
|
gp160(88-96) | observed variant |
NVTEdFNMW
|
gp160(88-96) | escape documented in this paper; replicative capacity/ fitness enhanced; observed variant |
NVTEeFNMW
|
gp160(88-96) | escape documented in this paper; observed variant |
NVTEsFdMW
|
gp160(88-96) | escape documented in this paper; observed variant |
NVTEeFdMW
|
gp160(88-96) | escape documented in this paper; observed variant; replicative capacity is not abrogated |
NVTEeldMW
|
gp160(88-96) | escape documented in this paper; observed variant |
NVTEgFdMW
|
gp160(88-96) | escape documented in this paper; observed variant |
NVTEeFdMg
|
gp160(88-96) | escape documented in this paper; observed variant |
NVTENFNMW
|
gp160(88-96) | A*25:01 human epitope |
NVTEdFdMW
|
gp160(88-96) | escape documented in this paper |
NVTEeFdMW
|
gp160(88-96) | escape documented in this paper |
NVTEsFdMW
|
gp160(88-96) | escape documented in this paper |
NVTENFNMW
|
gp160(88-96) | A*25:01 human epitope |
NVTENFNMW
|
gp160(88-96) | A*25:01 human epitope |
NVTEdFdMW
|
gp160(88-96) | escape documented in this paper |
NVTEeFdMW
|
gp160(88-96) | escape documented in this paper |
NVTEsFdMW
|
gp160(88-96) | escape documented in this paper |
NVTENFNMW
|
gp160(88-96) | A*25:01 human epitope |
NVTEdFdMW
|
gp160(88-96) | diminished response |
NVTEeFdMW
|
gp160(88-96) | diminished response |
VTEEFNMWK
|
gp160(89-97) | human epitope |
VnEEFNMWK
|
gp160(89-97) | subtype-specific susceptible form |
VnEEFNMWe
|
gp160(89-97) | subtype-specific susceptible form |
VTENFNMWK
|
gp160(89-97) | human epitope |
VTENFNMWKN
|
gp160(89-98) | A11, A68 supertype human epitope |
TENFNMWKNNMVEQM
|
gp160(90-104) | human epitope |
TENFNMWKNNMVEQMHED
|
gp160(90-107) | human epitope |
KNFNMWKNDMVDQMHE
|
gp160(91-106) | human epitope |
NFNMWKNNMVEQMHEDIISL
|
gp160(92-111) | human epitope |
WKNDMVDQMHEDIIS
|
gp160(96-110) | human epitope |
WKNDMVDQMHEDIIS
|
gp160(96-110) | human epitope |